Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$1.36
+$0.03 · +2.26%
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Previous close
$1.36
+$0.03 · +2.26%
After-hours
$1.35
−$0.01 · -0.74%
Oct 9, 7:50 PM ET
Regular session · ET · Market data may be delayed.
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Day range
Current $1.36
52-week range
Current $1.36
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
41
Fair Value
Sentiment
67
Bullish
Risk
60
Elevated Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Day range
Current $1.36
52-week range
Current $1.36
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 3.18B USD | 4.94M USD | 4.6M USD | 4.14M USD | 1.09M USD |
| Cost of goods sold | 2.47B USD | 3.24M USD | 3.5M USD | 2.73M USD | 545.89K USD |
| Gross profit | 709.84M USD | 1.71M USD | 1.1M USD | 1.4M USD | 543.55K USD |
| Research and development | 15.13M USD | 2.85M USD | 3.22M USD | 3.73M USD | 7.28M USD |
| Selling, general, and administrative | 1.88B USD | 6.56M USD | 5.8M USD | 5.85M USD | 6.87M USD |
| Operating expenses | 9.19M USD | 9.62M USD | 9.24M USD | 9.78M USD | 14.34M USD |
| Interest income | 244.97K USD | 156.54K USD | 721.97K USD | 652.37K USD | 123.72K USD |
| Interest expense | 10.7K USD | 373.11K USD | — | — | — |
| Depreciation and amortization | 708.36K USD | 534.73K USD | 604.52K USD | 596K USD | 511.79K USD |
| Operating income | −9.9M USD | −7.92M USD | −8.13M USD | −8.38M USD | −13.79M USD |
| Net income | −12.56M USD | −8.16M USD | −7.68M USD | −7.95M USD | −18.6M USD |
Company facts updated Oct 10, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
